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The main body of this thesis in Chapter III is a journal article entitled “Ciprofloxacin and 
Rifampin Dual Antibiotic-Loaded Biopolymer Chitosan Sponge for Bacterial Inhibition.” This 































 Increases in patients’ costs, multiple surgeries, and difficult treatment solutions are 
resultants of musculoskeletal infections. The presence of biofilm-forming or antibiotic resistant 
bacteria exponentially increase the complexity and complications in treatment of those 
musculoskeletal infections. During this study, the combination of ciprofloxacin and rifampin 
loaded in and released from chitosan-based local delivery systems was evaluated as an adjuvant 
therapy for prompt reduction of biofilm-forming bacteria in the wound when locally delivered. 
Primary assessments included antibiotic release, sponge eluate in vitro activity, in vitro synergy 
assays, effect on chitosan sponge pore structure, and an in vivo implant associated biofilm 
functional model. Antibiotic activity was present through seven days against S. aureus and P. 
aeruginosa. Ciprofloxacin had a therapeutic elution profile that lasted, at least, seven days while 
rifampin’s lasted three days. Additive effects were present against P. aeruginosa during the in 
vitro synergy assay with inconclusive results against S. aureus. No unexpected or adverse effects 
on chitosan sponge pore structure were seen after sponges were loaded with the antibiotic 
cocktail. Complete clearance of biofilm-forming S. aureus and E. coli with no noticeable adverse 
effects were achieved in the functional infected pin murine model. The results of this study 
support the potential use of ciprofloxacin and rifampin in chitosan-based and other local delivery 
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Statement of Clinical Problem  
Of all injuries in the United States one of the more prevalent types are complex 
musculoskeletal wounds, which may experience compromised wound healing as a result of 
bacterial infection.1 Civilians are estimated to have a 20% chance of infection in open fracture 
wounds with soldiers having estimates up to 65% if an open fracture wound is the result of a 
high-energy trauma.1-3 Bone fixation devices may be required to ameliorate traumatic injuries to 
the musculoskeletal system. According to estimates, incidences of open fracture and extremity 
trauma are estimated to be six million or more each year in the United States.4  Infection rates of 
5% are seen when fixation devices are implemented in musculoskeletal injuries.5  Recently 
released estimates from the American Academy of Orthopedic Surgeons (AAOS) reflect over 
500,000 surgical site infections (SSI) occurring per year subsequent to an orthopedic procedure.6 
It was reported between October 2005 – December that 14.8% of total hip arthroplasty (THA) 
revisions were due to infection.7 Occurrence of bacterial resistance is increasing, magnifying an 
already difficult treatment prospect of musculoskeletal infections.6  Adverse effects may result 
from an increase in systemic antibiotic administration.8 Some current solutions such as 
poly(methyl methacrylate) beads offer minimal to no degradation, requiring an additional 
surgery for removal.9, 10 Treatment solutions incorporating calcium sulfate may experience the 
onset of excessive fluid accumulation and wound drainage resulting from rapid degradation.11 
Engineered inexpensive biodegradable devices, loaded with widely available antibiotics, could 
be advantageous to reduce or prevent SSIs in orthopaedic procedures and especially in 
2 
 
conjunction with the regimen aimed at complex extremity wounds coalesced with fracture 
fixation devices.      
Hypothesis and Research Objectives 
It was hypothesized that engineered porous chitosan sponges, after being hydrated with 
ciprofloxacin and rifampin for short-term treatment, less than 14 days, will be effective as an 
adjunctive therapy for infection inhibition. Other goals include maintaining elution kinetics to 
maintain diffusion of active antibiotics to inhibit establishment of bacterial infections in 
musculoskeletal injuries, cytocompatibility, and capability of point-of-care loading. The specific 
objectives of this research are as follows:   
1. Maintain bactericidal activity at or above minimal inhibitory concentrations against 
biofilm-forming P. aeruginosa and S. aureus of ciprofloxacin and rifampin after being 
eluted from chitosan-based local delivery device 
2. Possess biodegradable characteristics in chitosan-based sponges that will eliminate need 
of additional surgery for removal, after application, of local delivery device  
3. Possess cytocompatibility/biocompatibility properties of chitosan-based local delivery 
device that support use in infection prevention applications 
4. In vitro delivery of ciprofloxacin and rifampin from the chitosan-based sponges sustained 
through, at least, 7 days at active levels against biofilm-forming S. aureus and P. 
aeruginosa to prevent colonization 
5. In vivo delivery of ciprofloxacin and rifampin from chitosan-based sponges over, at 
minimum, 7 days for inhibition of bacterial infection resulting from biofilm-forming S. 





Wounds and Healing Process 
Musculoskeletal wound infections may develop from traumatic injuries, surgical wounds, 
acute wounds lacking proper treatment, or from an accompanying co-morbidity; and may 
prevent normal patient healing and recovery.12 Peripheral vascular disease, diabetes, 
malnutrition, and chronic steroid use are some co-morbidities which can impair tissue healing 
and contribute to the occurrence of surgical site and wound infections.13 High-energy fractures 
where the bone penetrates the skin, compromises vasculature and communicates with extra-
tissue environment—open fracture—is an extreme case of traumatic musculoskeletal wound.14 
Open fractures are more likely to establish bacterial colonization when compared to surgically 
created wounds.15 Emotional, physical, and monetary stress experienced by the patient resulting 
from musculoskeletal wounds are also high.7 
Impairment of normal physiology resulting from damage to muscle, skin, bone, or other 
tissue is referred to as a wound.16 Innate responses in efforts to repair the wound occurs in a 
series of six steps normally. Rapid hemostasis is primary after a wound is initiated, which is the 
mechanism that stops the bleeding.16 Vasoconstriction, tight closing of blood vessels, of wound 
feeding vessels and clotting are the body’s mechanisms normally used to achieve this goal.16 
Inflammation is the body’s way to signify an injury it is secondary/simultaneous to hemostasis. 
Healthy cells are being directed to the wound site during the process of inflammation and is one 
reason why inflammation is vital in the wound care process.16 However, inflammation can be 
detrimental to wound healing by preventing regeneration if it prolongs. There are four primary 
symptoms associated with inflammation, redness, swelling, heat, and pain. As inflammation is 
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occurring several types of cells are being released including ones for migration and proliferation. 
Movement of cells in an extremely coordinated and specific order happens with migration 
function. Further constriction of blood vessels, like hemostasis, happens under proliferation. As 
bleeding becomes controlled the body begins engaging in rebuilding tissue. The formation of 
new blood vessels during a process referred to as angiogenesis is the primary step in the 
rebuilding process. Damaged veins and arteries are beginning to be replaced through either 
creation of new sections or with addition to existing sections. After angiogenesis is the 
replacement of compromised skin, known as re-epithelialization. Keratinocytes, which comprise 
the epidermis, are proliferating and migrating to cover the wound from the environment during 
this phase.16 During this phase, several layers are created each working in tandem to prevent loss 
of fluid and provide protection.16 These are innate would healing processes that most humans 
possess and employ if a wound is experienced. There are several instances when the innate 
processes may be overwhelmed and require an assist, some musculoskeletal wound infections 
are a prime example. 
Various cells types have specific roles in hemostasis, inflammation, proliferation, and 
remodeling, which are aspects of innate wound healing.17 Neutrophils migrate from the blood to 
remove foreign bodies, bacteria, non-viable tissue and other debris from the wound site within 
the first eight hours.18 Maximal concentration of neutrophils at the site of the wound is reported 
to occur in 24 – 48 h with decreased concentration beginning 72 h after wound induction.19 
Macrophages and mast cells become responsible for the cleansing process as neutrophils 
evacuate the wound site.20 Epithelial cells construct a thin epithelial layer over the wound, 
closing it from the external environment after the wound is clean and disinfected, which occurs 
approximately after 48 – 72 h.21, 22 Subsequent to the cellular/tissue responses discussed 
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previously, remodeling is initiated and persists, on average, 4 – 8 weeks depending on the 
severity of the wound.23   
Wound Management  
Effective management of the wound can assist the patient’s innate response in restoration 
of function to the wound site. A reduction in morbidity with improved prognosis is seen through 
the prevention of complications in the healing process.24 Debridement, irrigation, fixation, 
closure and infection prevention are main principles of complex musculoskeletal wound 
management.25 Currently, no universal standard exists in application of these principles by 
surgeons.26 
The process of debridement removes foreign and non-viable tissue from the wound.27 
Necrotic tissue is the ultimate product of non-viable tissue and inhibits wound healing with the 
promotion of microbe growth and the blockage of the host’s inherent tissue defenses.27 As a 
result, debridement of skin and subcutaneous tissue is executed until capillary bleeding is 
visualized.26 Additional debridement may be recommended after 24 – 48 h depending on the 
degree of soft tissue damage or contamination.28  
Removal of smaller foreign bodies coupled with the reduction in bacterial concentration 
is known as irrigation or lavage. While there is some variation in irrigation procedures, in 
general copious amounts (approximately 10 L) of irrigation fluid are used to help remove small 
foreign bodies and bacteria from wound site.28 When ballistic or explosion wounds are present 
irrigation is essential due to the potential for the bacteria to spread along tissue planes.29 In 
efforts to minimize patient infection, antimicrobial administration by means of irrigation also 
may be implemented.30 The knowledge level of the presiding surgeon regarding the wound 
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affords them the opportunity to tailor the antibiotic lavage treatment for specific suspected 
bacterial contaminate.31 
Further bone and soft tissue damage is inhibited by wound fixation and closure, which 
provides an initiation point for inherent wound healing procedures.32 Several methods for 
internal fracture stabilization exist including, but not limited to, intramedullary nails, plates and 
screws with each possessing pros and cons.33 Intramedullary nails are effective when fixation of 
lower extremity fractures are sought, however there are possibilities that bone circulation may be 
disrupted.34, 35 Plates and screws are often employed when precision is needed for a fractured 
bone alignment and are mostly used in upper extremity and transarticular fractures.36, 37 For more 
advanced wounds entailing crushed or pulverized bone and surrounding soft tissue damage, 
treatment solutions may include internal fixation devices such as rods and scaffolds composed 
from titanium or stainless steel alloys or external devices consisting of frame and pins.38, 39 When 
considering prosthesis associated with surgical procedures performed during total hip and total 
knee arthroplasties material fixation becomes critical.40 Closure of wounds may be achieved with 
available soft tissues, depending on whether adequate coverage is possible, or soft tissue 
reconstruction from local or free muscle flaps.32 The surgeon may, ultimately, be constricted to 
amputation due to damage or infection.28  
Wound Infection 
Prevention is often the most desired goal in infection treatment, however approximately 
65% of patients with severe, open wounds have microorganism contamination.2 
Among the six million fractures occurring every year, 5 – 10% will entail additional treatment 
for compromised healing resulting from improper fracture fixation, bone resorption, vascular 
impairment or infection. Infection risks are increased if co-morbidities preexist and once 
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infection is established symptoms may include fever, chills, headache and stiffness to pain, 
erythema and wound drainage.2 Imaging, microbiological cultures, blood tests, and polymerase 
chain reaction (PCR) techniques are infection diagnostic tools.41-43 Systemic antibacterial therapy 
is a technique that does not involve surgery as an initial treatment.44 Long term effects of wound 
infections include revision surgeries, continued antibiotic treatments, possible recurrence of 
infection, prolonged wound healing and reduced quality of life, which all contribute to increased 
medical costs.42 Potential clinical outcomes include patient death or treatment failure.45, 46 Within 
the United States surgical site infections (SSI) are accountable for an approximate $1.6 billion 
inflation in healthcare costs per year.47 Estimates for average attributable costs of SSIs include 
estimates ranging from $10,443 (2005 dollars)48 to $25,546 (2002 dollars)49 per infection. 
According to a Centers for Disease Control and Prevention report by Scott et al., the infection 
site with the largest range of annual costs is SSI $3.2 billion to $8.6 billion using the Consumer 
Price Index for all urban consumers (CPI-U) and $3.5 billion to $10 billion using the Consumer 
Price Index (CPI) for inpatient hospital services.50 The CPI-U is constructed by the U.S Bureau 
of Labor Statistics and is a measure of the average change over time in prices paid by all urban 
consumers (defined as all urban households in Metropolitan Statistical Areas and in urban places 
of 2500 inhabitants or more) for a market basket of consumer goods and services purchased for 
day-to-day living.50  
Staphylococcus aureus (S. aureus), Staphylococcus epidermidis (S. epidermidis) and 
Pseudomonas aeruginosa (P. aeruginosa) are common in musculoskeletal wounds.2 Often 
isolated from the skin and gastrointestinal (GI) tract of healthy individuals’ flora with the ability 
to cause disease when introduced to wound sites.2 S. aureus is commonly found in 
musculoskeletal infections consisting of  osteomyelitis, arthritis, myositis, or implanted 
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orthopaedic devices and arises in roughly 50% of all infections.2, 51 S. aureus is reported as the 
leading cause of osteomyelitis and nongonococcal bacterial arthritis52 and a prominent cause of 
prosthetic joint infection.2, 5 Escalation of the problem was seen in the 90’s as S. aureus began to 
exhibit resistance to certain antibiotics.45 S. aureus resistance nullifies the effectiveness of many 
β-lactam antibiotics, including methicillin specific antibiotics, which act to inhibit Gram-positive 
bacteria’s peptidoglycan cell wall synthesis.42 Methicillin resistant Staphylococcus aureus 
(MRSA) infections have seen an increase from 35.9% in 1992 to 64.4% in 2003 for S. aureus 
isolates collected in the United States.45, 46 The American Academy for Orthopedic Research 
recently indicated the death rate from MRSA is 2.5 times greater than its non-resistant 
counterpart.5 Propagation of vancomycin resistant S. aureus (VRSA) is a grave concern.53, 54 The 
resistance to vancomycin by S. aureus has seen increasing importance in nosocomial pathogens 
in the United States, but to date has seen little occurrence in osteomyelitis.55  
The commonly reported infection rate through prophylactic antibiotics and aseptic 
techniques for uncontaminated surgical wounds is 1%, however for open fractures the rate is 
approximately 50%.12 A wide-spectrum of Gram-positive and Gram-negative specific 
antimicrobial agents are commonly administered to open fracture wounds to prevent 
contamination. Bacteria may adhere to wound tissue and on implanted biomaterial surfaces 
subsequently forming an enclosed film of polysaccharides, ions, nutrients, and other 
environmental constituents as a mechanism of survival.56 Adhered bacteria are known as biofilm. 
According to reports the increase in biofilm related bacterial resistance is amplified by the 
increase in betalactamase concentration within the biofilm and the inability of antibiotic to 
penetrate biofilm.5 The presence of implant devices strengthens the likelihood of infection and 
biofilm, making implant materials an infection risk factor.56, 57 
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Implant Associated Infection 
Host defense weaknesses that allow bacteria to become established are exploited in 
orthopaedics with implant concomitant post-surgical infections.56 Currently, simple debridement 
and irrigation procedures allied with antimicrobial agents are not always efficacious in 
prevention of infection specifically with open fractures, which have an infection rate of 50%.14, 58 
Due to the large population of patients receiving orthopaedic implants with an infection rate of 1 
- 5% for those involving total joint replacement, infections related to implants are considered 
prime for novel research in infection prevention treatments.5, 7, 56 Often, additional surgeries for 
implant removal and replacement are the only option for infection eradication. Bacteria are 
passively or actively adsorbed after implantation on biomaterial surfaces leading to biofilm 
formation. One fundamental pathogenic mechanism in biomaterial-centered sepsis is microbial 
colonization followed by adjacent tissue damage.56 Main pathogenic species of orthopaedic 
clinical isolates related to infections linked to implants are 34% S. aureus, 32% S. epi, 13% 
coagulase negative staphylococci, 6% pseudomonas, 5% enterococcus, and 11% other species.2 
A vast majority of infections associated with implants in orthopaedics are the result of Gram-
positive aerobes, primarily staphylococci.6   
Increases in morbidity, mortality and socioeconomic costs can be attributed to 
biomaterial-centered infections.47 Preventing infection formation is an ongoing and growing 
challenge to implant development.28, 56 Areas for improvement include more efficacious 
antibiotic treatment of implant associated infections and traumatic musculoskeletal wounds.  
Antibiotic Therapy 
Selection of antibiotics for the treatment of musculoskeletal infection may be 
distinguished by three phases: 1st visual, 2nd definitive treatment, and 3rd treatment 
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confirmation.59 The risk of infection in patients with severe wounds is reduced with early 
antibiotic administration.44 The selection of antibiotics by the attending physician or clinician is 
constrained by their ability to target the bacteria commonly seen in infections that the patients 
are deemed to be at risk for. Increases in the occurrence of antibacterial resistance magnifies the 
arduous task of  combating musculoskeletal wound infections.44 Due to recent advancements, 
wound screening has the ability to identify the presence of certain microbes prior to treatment.6, 
41 With early dispensation of selected antibiotic therapy the effectiveness has improved, aiding in 
limiting exposure and preventing infection.59  
Quinolones/fluoroquinolones have proven to be effective against Gram-negative and 
some Gram-positive bacteria due to their ability to prevent the DNA from unwinding and 
duplicating.60 Principally, quinolones/fluoroquinolones target DNA gyrase and topoisomerase 
IV, which are both bacterial type II topoisomerases.61 DNA gyrase is a tetramer enzyme with 
two GyrA and two GyrB subunits that catalyze the introduction of negative superficial turns into, 
and elimination of positive supercoils from, the replication fork into the double-stranded 
covalently closed circular DNA.62 DNA gyrase acts before the replication fork, preventing 
replication-induced structural changes.63 Topoisomerase IV acts behind the replicating fork and 
catalyzes the removal of supercoils and decantation of interlocked daughter DNA molecules.64 
Both DNA gyrase and topoisomerase IV appear to be targeted by all quinolones, regardless of 
bacterial species.62 In Gram-negative bacteria, DNA gyrase is generally bound more readily by 
quinolones.62 Topoisomerase IV is preferred in Gram-positive bacteria.65, 66 Although this effect 
on bacteria by quinolones has proven useful and have successfully prevented the duplication of 
certain bacteria, quinolones alone have proven ineffective, comparable to other classes of 
antibiotics, against biofilm when used alone.67-71 Ciprofloxacin is a 2nd generation 
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fluoroquinolone that has been clinically effective at inhibiting Gram-negative and some Gram-
positive bacteria.67-76 Second-generation quinolones are fluorinated quinolones discovered in the 
mid-1980s.62 The fluorine atom and piperdine positioning result in a much broader spectrum of 
activity that includes P. aeruginosa and some Gram-positive bacteria, such as S. aureus, and 
improved bioactivity.62 While ciprofloxacin has shown the ability to penetrate biofilm, bacterial 
resistance has also been developed.77 Ciprofloxacin is one of the numerous fluoroquinolones that 
have extensive clinical usage for the treatment of Gram-negative and some Gram-positive 
bacterial pathogens.63, 65, 66, 78-83 Potential acquired resistance to ciprofloxacin, along with 
massive list of other antibiotics, presents challenges that require novel approaches.60, 67, 68, 84-95 
Among these novel approaches is the usage of antibiotics in combinations that may facilitate 
possible synergism of each antibiotic’s active mechanism against polymicrobials. However, 
systemic administration of ciprofloxacin has recently been noted to cause adverse side-effects 
involving tendons, muscles, joints, nerves and the central nervous system by the FDA.96 
 Rifampin has emerged as a major player in antibiotic combination therapy for its ability 
to combat biofilm among other infections. Rifampin, a type of rifamycin, specifically inhibits 
bacterial DNA-dependent RNA polymerase by blocking the RNA chain initiation step of 
bacterial DNA transcription to messenger RNA that is needed to synthesize bacterial proteins.97 
Rifampin is employed as part of combination regimens against mycobacterial infections and 
some Gram-positive bacterial infections, such as S. aureus and S. epidermis.62 Rifampin is 
bactericidal against Gram-positive bacteria and diffuses well into biofilm where it perpetuates its 
bactericidal ability.62 Disruption of biofilm is within the scope of rifampin, however rifampin-
resistant mutants may be selected.62 Rifampin requires administration in conjunction with other 
antibiotics as a result.62 Prior in vitro studies have demonstrated rapid synergy when rifampin is 
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incorporated with a β-lactam and slower synergy with vancomycin.89, 97, 98 Synergy is defined in 
the medical dictionary as the correlated action or cooperation by two or more structures or drugs. 
Synergism is the state at which the combined action is greater than the sum of each acting 
separately. Rifamycins bind very tightly to the β-subunit of the RNA polymerase in a molar ratio 
1:1.62 In contrast they do not bind well to the β-subunits isolated from rifamycin-resistant 
mutants and mutations are found in the β-subunits of RNA polymerase in such mutants that aid 
in a reduction of rifampin binding to β-subunits of RNA polymerase.62 There is currently no 
evidence to support an effect on mammalian enzymes by rifampin.62 Rifamycins also modify 
bacterial pathogenicity and may alter attachment and tissue toxicity.99-101 The World Health 
Organization’s List of Essential Medicines includes rifampin and ciprofloxacin. Multiple 
investigations are ongoing consisting of rifampin in combination with other infection reducing 
agents.88, 89, 102-116 Resistance to rifampin, despite its contrivance, has been demonstrated to 
develop quickly.56, 117-120 Monotherapy is rarely incorporated as a result.56, 117-120 Due to their 
methods of action, antibiotics must be in contact with their bacterial targets to be effective.121, 122 
Some antibiotics may be delivered to the infection site either systemically or locally, while some 
are delegated to being delivered locally.123  
Localized Drug Delivery 
Drug delivery using intravenous or oral routes is well established, however those 
methods may possess undesired effects related to the distance from the injection site or digestive 
system; in addition to the biochemical environment that must be navigated before the drug 
reaches the wound.124 The success of antibiotic therapy depends on keeping low, nontoxic levels 
systemically and high levels in the infection tissue.8 Local therapy using antibiotic-loaded 
delivery vehicles have been utilized adjunctive to systemic antibiotic therapy for open wound 
13 
 
and fracture treatments. Antibiotic release from the delivery mechanism into the surrounding 
tissue is referred to as elution, which is facilitated by increased surface area/volume ratio and 
high concentrations of loaded antibiotics.124 Protracted release of drugs, which may lead to high 
local levels of bioactive antibiotics with negligible serum levels are obtainable using this 
technique.125 Bone penetration is not actively observed with systemically administered 
antimicrobial agents, in contrast high local levels of antibiotics enable antibiotic delivery through 
diffusion to bone and avascular areas of wounds.8 Through the utilization of local drug delivery 
potency is maximized at infection site, while minimizing systemic toxicity risk generating an 
efficacious delivery system.10  
Efficacy of local drug delivery may be improved with the insertion of local biodegradable 
delivery devices.126 Biodegradable materials are broken down with hydrolytic mechanisms with 
or without supplemental enzymatic mechanisms. A primary advantage of biodegradable systems 
is the circumvention of subsequent surgeries to remove the foreign drug delivery device. 
Implantation at the site of the wound allows the drug to be delivered at amplified concentrations 
with minimal delay between delivery and action, with degradation occurring naturally over time. 
The reported status of local drug delivery in an article by McLaren, stated that all are pre-loaded 
with antibiotics during the manufacturing process, referred to PMMA and calcium sulfate 
(CaS).10 McLaren concluded that no polymer was easily mixed with antibiotics in the operating 
room or in situ-loaded for clinical use.10 In situ-loading would offer the advantage of being 
implemented locally at the site of the wound or infection at the time of treatment, which chitosan 




Chitosan may be used to fabricate local biodegradable delivery devices. Chitosan is a 
linear polysaccharide composed of randomly distributed β-(1-4)-2-amino-2-D-glucosamine 
(deacetylated) and β-(1-4)-2-acetamido-2-D-glucoseamine (acetylated) units.127 The second most 
abundant naturally occurring polymer, chitin, is used to derive chitosan.128 Chitin is a white, hard 
and inelastic nitrogenous polysaccharide that is isolated from exoskeletons of crustaceans. Strong 
alkaline solution is the major procedure used for obtaining chitosan by alkaline deacetylation of 
chitin.129 The raw material is crushed, washed with water or detergent and ground into small 
pieces prior to processing. The abundance of acetyl units is the chemical difference between 
chitosan and chitin. Chitosan’s performance is impacted by its degree of deacetylation (DDA).130, 
131 When the DDA is greater than 50% the copolymer is termed chitosan. Chitosan possesses a 
weak cationic base, is insoluble in water and organic solvents but is soluble in dilute acidic 
solutions, which may include acetic, citric, formic or lactic acid.130, 132 Negatively charged 
surfaces are bound by chitosan due to bioadhesive properties resulting from its charges 
(NH3+).133 Chitosan is characterized as biodegradable,128, 134, 135 antibacterial127, 136 and possesses 
ability to be loaded with and release drugs over time.124, 136-138 
The level of chitosan’s DDA affects degradability with DDA close to 50% being highly 
degradable in vivo, however when DDA is greater than 95% chitosan may remain in vivo for 
months even years.139 Lysozyme, N-acetyl-o-glucosamindase, and lipases degrade chitosan 
within the body. Lysozyme degrades chitosan by cleaving the glycosidic bonds between the 
repeating units, with byproducts of saccharides and glucosamines which are incorporated into 
glycoproteins or excreted as carbon dioxide.140 Chitosan’s saccharide degradation products do 
not elicit chronic foreign body reactions because of gradual absorbtion by the human body.128 In 
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contrast, when chitosan is more crystalline, normally due to high DDA, the chains are closely 
packed averting lysozyme interaction which reduces degradation capacity.139 Implementation of 
chitosan in a biodegradable local delivery system for antibiotics obviates the need for a removal 
surgery, reducing the total cost and trauma to the patient in comparison to other local antibiotic 
delivery devices such as polymethylmethacrylate (PMMA) beads.128  
Over 200 applications incorporating chitin, chitosan or a derivative are being investigated 
or in practice.127, 129 Cosmetics, agriculture, food, biomedical and textile industries are a few 
examples of the applications. For medical uses, chitosan may be used as a component of wound 
dressings,141, 142 bioactive coatings for orthopaedic and craniofacial implants 58, 143 and drug 
delivery systems amongst many others.144-150 Chitosan-based drug delivery systems have been 
loaded with several types of drug molecules, including vancomycin146, amikacin149, 
gentamicin145, daptomycin149, prednisolone148, rhBMP-2151, rifampin152, ciprofloxacin.153 
Chitosan has the ability to rapidly clot blood when partially dehydrated, which enables its usage 
as a bandage or hemostatic agent.145 Fully hydrated chitosan contains properties that allows it to 
rapidly rehydrate and absorb drugs.141  
Biofilm 
The formation of biofilm, surface-adhering bacteria, presents challenges that are either 
costly or exceptionally difficult to overcome in wound treatment, particularly musculoskeletal 
wounds.95 Once the formation of the biofilm is detected effectual eradication has proven to be 
arduous. Biofilm treatment hurdles include the direct communication between the bacteria 
through the elaboration and recognition of small molecules.154 Staphylococcus aureus and 
Pseudomonas aeruginosa bacterial strains have been discovered to be among the most common 
culprits in biofilm.74, 94 Various antibiotics that possess high levels of activity against many 
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planktonic bacteria have been evaluated against those same bacteria in a biofilm with little to no 
success of inhibition. Some studies have demonstrated the ability of several antibiotics to 
infiltrate bacteria and prevent further growth, however the most effective classes of those same 
antibiotics against biofilm have revealed bacterial recurrence when used singularly.114, 155, 156 
Reduction in antibiotic vulnerability in the biofilm bacteria is a key component of the potential 
failure to inhibit or the recurrence.155 
Biofilm infections that are related to implant devices are problematic because the bacteria 
has the ability to adhere and form the biofilm on these foreign materials.91 Microbial 
colonization has been implicated as the main causative factor in the pathogenesis of implant 
failures.157-159 Treatment of implant related biofilm, if unsuccessful, might require additional 
surgeries to remove the infected tissue or implant component.160, 161 Developing a treatment 
method that reduces the required removal of implants due to the formation of biofilm is 
immensely critical. Patient comfort, costs to patient and/or insurance company (private, 
company-sponsored or public) and additional potential complications are all concerns once the 
implant-based biofilm requires removal for adequate management.50, 56  
Summary 
Domestically, infected musculoskeletal wound treatments present challenges that appear 
perpetual with as much ongoing research in efforts to combat them. The current methods of 
wound debridement, lavage, and fixation are not able to prevent all infections when instigated 
solitarily. Infection prevention and wound promotion within the first 72 – 168 hours are crucial 
objectives that should be met.32 An increase in antibiotic resistant organisms coupled with the 
increasing number of surgical site infections are two rising concerns.43, 45 Rifampin is a viable 
candidate for the treatment of Gram-positive and resistant S. aureus when used in conjunction 
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with another antibiotic.74, 116, 162-164 Ciprofloxacin has shown some success against Gram-
negative bacteria while being investigated for various applications, making it a feasible 
aspirant.72, 74, 165, 166 Local delivery of antibiotics with a biodegradable chitosan sponge would be 
advantageous for adjunctive musculoskeletal wound treatment. The aim of this research is to (1) 
determine if the combination of ciprofloxacin and rifampin is efficacious in inhibiting the 
bacteria known to be present in biofilm when delivered from a chitosan-based delivery device, 
(2) allow the surgeon or medical provider to load this antibiotic cocktail in situ, and (3) sustain 
antibiotic elution and degradation properties to be applicable as a surgically adaptable device 
wrap or for wound coverage.     
Hypothesis  
It is hypothesized that engineered porous chitosan sponges, after being hydrated with 
ciprofloxacin and rifampin as a short-term adjunctive treatment, less than 14 days, will be 
effective at biofilm-related infection prevention when situated on or around implanted devices or 
on traumatic wounds. The sponge will elute antibiotics while biodegrading to inhibit infection, 
which may develop into biofilm, thus eliminating surgical need for removal of local delivery 
device.    
CHAPTER III 




Complex extremity wounds in Wounded Warriors can become contaminated with 
microbes, which may lead to amputation, morbidity, or even fatality. Local delivery of multiple 
or broad-spectrum antibiotics allows practicing clinicians treatment solutions that may inhibit 
implant-associated infection. The development of vancomycin-resistant S. aureus (VRSA) has 
become a critical challenge in nosocomial infection prevention in the United States. As an 
alternative to vancomycin in combination with another antibiotic, locally delivered ciprofloxacin 
and rifampin were investigated in a preclinical model for the prevention of biofilm in complex 
extremity wounds with implanted fixation device. In vitro assays demonstrated ciprofloxacin and 
rifampin possess an additive effect against Gram-negative P. aeruginosa and were actively 
eluted from a chitosan sponge based local delivery system. In an in vivo orthopaedic hardware-
associated polymicrobial model (S. aureus and E. coli) the combination could achieve complete 
clearance of both bacterial strains. E. coli was detected in bone of untreated animals, but did not 
form biofilm on wires. Results reveal the clinical potential of antibiotic-loaded chitosan sponges 
to inhibit infection through tailored antibiotic selection at desired concentrations with efficacy 
towards biofilm inhibition. 
INTRODUCTION 
Bone fixation devices may be required to ameliorate traumatic injuries and some 
procedures to the musculoskeletal system. According to estimates, open fracture and extremity 
trauma are estimated to be six million or more each year in the United States (US).4  Infection 
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rates of 5% are seen when fixation devices are implemented in musculoskeletal injuries.5  
Wound infection remains a major cause of morbidity and mortality in US military Service 
members who experience nonfatal combat-related injuries, notwithstanding current innovations 
in medical treatment options.167  Wound infection studies of blast injury resulting from combat 
operations report several contributing factors, including but not limited to, pathogen, injury type 
and severity, study population, infection outcome, and geographic zones. These studies reveal 
that US military personnel have combat-related infection rates ranging from 5.5% to 49%.168 
Multiple factors may contribute to development of musculoskeletal wound infections, including 
but not limited to, traumatic injuries, surgical wounds, delayed definitive treatment method of 
acute wounds, or accompanying co-morbidities, which impedes the innate healing process and 
patient recovery. Rate of occurrence of bacterial resistance to antibiotics is increasing for 
musculoskeletal infections, magnifying an already difficult treatment prospect.6  Socioeconomic 
costs have increased due to the contribution of complications resulting from infection.28  
Engineered inexpensive biodegradable local delivery devices, loaded with widely available 
antibiotics, could be advantageous to prevent infection, especially infections resulting from 
biofilm formation on fracture fixation devices. 169-172 More than 65% of infections being treated 
in the developed world are caused by biofilm forming bacteria.173    
Injuries that result from combat-related blasts possess a high probability of infection due 
to the complexity of the wounds and the existence of environmental contaminants, with some 
studies showing biofilm forming within a matter of hours after injury.174 Injuries received on the 
battlefield are further complicated when Staphylococcus aureus (S. aureus) and Pseudomonas 
aeruginosa (P. aeruginosa) are involved. These bacteria are the most prevalent Gram-positive 
and Gram-negative pathogens and are attributed with 75% of biofilm infections on medical 
19 
 
devices.174, 175 Escherichia coli (E. coli) and P. aeruginosa were two of the more frequent 
bacterial strains reported during recent military operations, with verified presence in 14% of 
wounds.175 Delay of return to duty, an increase in hospitalization associated costs, and/or 
permanent incapacitation are sequelae that may result from the treatment of infections.161, 175-177 
Infection prevention after an injury is a principal strategy in managing combat-related 
trauma, with administration of systemic antibiotics within three hours of injury to reduce the 
chance of wound infection and bacterial colonization being the primary care option utilized.174, 
176 Local delivery systems for antibiotics, such as antibiotic-loaded poly(methyl methacrylate) 
beads (PMMA) and calcium sulfate, are growing in acceptance as an adjunctive approach to 
systemic delivery.178-180  Local delivery systems may be advantageous over systemic 
administration in that they deliver higher concentrations of antibiotic directly to the affected 
tissue178 and minimize risk of toxicity to organs.179, 181-183 PMMA beads are non-degradable and 
require an additional surgery to remove the implanted material for complete wound healing. 
Additionally, once PMMA beads have released their antibiotic load, they provide surfaces for 
potential biofilm formation.184 Rapid resorption of calcium sulfate pellets results in calcium-rich 
fluid that incites an inflammatory response and wound drainage.11  The ability to load a local 
delivery device with broad spectrum or multiple antibiotics by the attending clinician at the time 
of intervention may reduce the incidence of  polymicrobial contamination. Local antibiotic 
delivery systems should possess the capability for an extended release profile, biocompatibility, 
biodegradability with biocompatible degradation products, and personalized antimicrobial 
selection depending on the individual and what bacteria are being targeted.185 
Chitosan, an adaptable natural biopolymer, has been used to fabricate a myriad of drug 
delivery systems,185-187 including lyophilized sponges.188 Commercially available chitosan 
20 
 
wound dressings in the form of a sponge were approved by the FDA for wound management, 
possessing the ability to be hydrated with solutions for applications involving varying degrees of 
musculoskeletal wounds. Practicing physicians, at their clinical discretion, may choose to include 
antibiotics in the hydrating solution in their treatment solution of contaminated or infected 
traumatic injuries.189, 190 FDA clearance of antibiotic introduction into the hydrating solution has 
not been specifically obtained in any approved local delivery device including PMMA and 
calcium sulfate. Chitosan sponges have shown excellent biocompatibility, degradability, and 
may be loaded with countless antibiotics by inert absorption and diffusion.170, 185, 188, 190, 191 
Sponge fabrication allows for varying thicknesses and pore sizes using a lyophilization process, 
permitting the release of antibiotic solutions to be tailorable,188, 192 with geometry that can be 
customized for treatment of complex wounds. This study seeks to investigate the effects of 
combining ciprofloxacin (Cipro) and rifampin (Rif) for local delivery from chitosan-based 
sponges for infection prevention. In vitro and in vivo tests were used to evaluate the efficacy of 
combined therapy of ciprofloxacin and rifampin against pathogens commonly associated with 
infection resulting from complex musculoskeletal wounds and/or implants. 
MATERIALS AND METHODS 
A sample size of 5 allows for detection of a difference of 6 µg mL-1 with an estimated 
standard deviation of 2.5 µg mL-1  in elution studies with power 0.80. The analysis was based on 
elution data obtained from previous studies conducted within the lab. This sample size was used 
throughout the study in all phases, except the in vivo animal model (n = 12) and a preliminary 




Chitopharm S chitosan was obtained from Chitinor AS (Tromsø, Norway) having an 82 ± 
2 DDA, 251 ± 17 kDa weight-average molecular weight (MW) and 2.013 ± 0.145 polydispersity 
index, all manufacturer reported values. Poly(ethylene glycol) (PEG) was purchased from Sigma 
Aldrich (St. Louis, MO, USA) having a 6 kDa MW.  
Sentrex BioSponge®, a chitosan-based approved wound dressing sponge, (Bionova 
Medical, Germantown, TN, USA) was included in the study due to its clinical use and 
commercial availability. 
Chitosan sponges containing 2.0% chitosan or 1.5% chitosan and 0.5% PEG were 
fabricated and used in all in vitro studies alongside BioSponge® (Bionova Medical, 
Germantown, TN, USA) except for the in vivo implant-associated biofilm model. BioSponge 
was the only chitosan sponge used for the in vivo animal model.   
Fabricated chitosan sponges, for all in vitro studies, were made by dissolving either 2.0% 
chitosan (w/v) or 0.5% poly(ethylene glycol) (PEG) and 1.5% chitosan (w/v) in 1% acidic (v/v) 
solutions. 188, 193  The solutions were placed in template containers with the desired shape and 
thickness and frozen at -20° C. Once frozen, the sponges were lyophilized, neutralized, frozen 
again, lyophilized again and then sterilized (Sterigenics, West Memphis, AR, USA) using low 
dose gamma radiation (25 – 40 kGy).  
Antibiotic Dissolution 
Targeted applications of the studies incorporated to test the efficacy of the Cipro/Rif 
combination required that the antibiotics be in solution. The dissolution of rifampin proved to be 
the most challenging aspect. Preliminary elution studies failed to address the solubility issue and 
the results (not shown) were comparable to prior studies.172, 193 However, it was later shown that 
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rifampin’s dissolution was not adequate for our targeted applications. Rifampin and its solubility 
was addressed by using 0.1 N hydrochloric acid (HCl) at 37° C with a final pH of 6.02. Scanning 
electron microscopy (SEM) images were taken to ensure that the solution pH value did not affect 
the structure or integrity of the chitosan sponges (Figs. 1, 2, and 3).                
 
FIGURE 1.SEM images of the BioSponge pre-hydration (top) and post-hydration (bottom). 
The sponge was hydrated in antibiotic solution for 10 minutes, which may be comparable 
for times in a clinical environment. As shown the pH of the hydrating solution was not 




FIGURE 2. SEM images of the 0.5% Peg/1.5% chitosan sponge pre-hydration (top) 
and post-hydration (bottom). The sponge was hydrated in antibiotic solution for 10 
minutes, which may be comparable for times in a clinical environment. As shown the 





FIGURE 3. SEM images of the 2.0% chitosan sponge pre-hydration (top) and post-
hydration (bottom). The sponge was hydrated in antibiotic solution for 10 minutes, 
which may be comparable for times in a clinical environment. As shown the pH of the 
hydrating solution was not adversely breaking down the structure. 
 
In Vitro Elution 
BioSponge, 2.0% chitosan, and 0.5% PEG/1.5% chitosan sponges were sectioned and 
weighed to nominal masses of 25 mg. The sponges were loaded with 5mg mL-1 of ciprofloxacin 
(Acros Organics, Geel, Belgium) and 5 mg mL-1 of rifampin (Fisher Scientific, Fair Lawn, New 
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Jersey, USA), the solvent was sterile 1X phosphate buffered saline (PBS). Each sponge was 
immersed in abundant ciprofloxacin and rifampin antibiotic solution (~10 mL) to allow 
hydration saturation. Sponge pre- and post-hydration masses were recorded to calculate 
approximate antibiotic solution volume absorbed into the samples. The sponge sections were 
gently placed within 125 mL NALGENE® containers with no impedance to natural structure, 
which allowed for adequate coverage by solution. Sterile 1X PBS (30 mL) was used to submerge 
the antibiotic-hydrated sectioned sponges. The submerged sponges were placed in an incubator 
(LabDoctor™ Mini Incubated Shaker, MidSci, St. Louis, MO, USA) at 37° C under constant 
motion (30 rpm). Samples of 15 mL each were taken at 1, 2, 3, 4, 5, 6, and 7 days. When the 
samples were taken, the PBS solution was refreshed. The samples that required PBS refreshment 
were returned to incubator until their time-period was reached, at which point the process 
repeated until all time points were elapsed. All sample collection and PBS exchange was 
conducted in an aseptic environment. Once samples were collected they were stored for eluate 
concentration analysis. Eluate sample storage was at -20 °C to prevent antibiotic degradation and 
maintain any active antibiotic activity.  
Eluate Concentration Analysis 
High-pressure liquid chromatography (HPLC), (UltiMate 3000, Thermo Scientific, West 
Palm Beach, FL, USA) was the analytical technique used to quantify the concentration of 
antibiotics in the sponge eluates. HPLC analysis for both antibiotics was modeled after a method 
used by Liu et al.194 Chromatographic separation was achieved by using a mixture of methanol-
acetonitrile-dipotassium phosphate (55 mM)-phosphoric acid (1.0M) (28:30:38:4, v/v) as the 
primary mobile phase (MP1), in addition to a buffer solution consisting of 55 mM K2HPO4 and 
1.0 M H3PO4 (MP2). Ciprofloxacin was read at λ = 280 bandwidth of 4 with a retention time of 
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2.38 minutes. Rifampin was read at λ = 333 bandwidth of 4 with a retention time of 11.21 
minutes. A gradient method was utilized with at a flow rate of 1.5 mL/min. Detection of 
ciprofloxacin occurred with MP2 at 60% and MP1 at 40% the gradient was then ramped up at 3 
minutes to 100% MP1 for the detection of rifampin. The concentrations of the antibiotics were 
measured to determine their elution profile over time.194-209  
In Vitro Antibiotic Activity 
The antibiotic activity was completed on two separate occasions due to the solubility 
concern.  
P. aeruginosa (ATCC 27317) was grown overnight at 37 °C in trypticase soy broth 
(TSB). The overnight growth was diluted 1:50 in TSB and 100 µL of this was added to plates of 
TSB agar and spread to make a lawn of bacteria. Once the lawn of bacteria was complete 6 mm 
blank discs (Beckton, Dickinson cat # 231039) were placed on the agar plates. After the 
placement of the disks was the addition of 20 µL of the sponge eluate to the disks. The plates 
were incubated for 24 h at 37 °C, pictures were taken and the diameter of the ZOI was recorded. 
Each plate contained five replicates for each group and time point. S. aureus (Cowan I ATCC 
12598) was grown and tested exactly as P. aeruginosa except for the dilution being 1:10. 
In vitro synergy assay 
Checkerboard synergy testing was performed using 96-well microtiter plates.   
Ciprofloxacin and rifampin were dissolved in phosphate buffered saline (PBS) and diluted in 
tryptic soy broth (TSB) in seven 2-fold dilutions from 4 µg mL-1 for ciprofloxacin plated against 
P. aeruginosa (ATCC 27317) and from 2 µg mL-1 plated against S. aureus (UAMS-1). Rifampin 
concentrations were from 256 µg mL-1 against S. aureus (UAMS-1) and from 0.06 µg mL-1 
against P. aeruginosa (ATCC 27317). Each solution was pipetted into triplicate wells of the 96-
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well plate. Positive and negative controls for this experiment were inoculating TSB, without 
antibiotics, with and without bacteria, respectively. Each well was inoculated with S. aureus 
(UAMS-1) or P. aeruginosa (ATCC 27317) for a final concentration of approximately 1 x 104 
CFUs per well. Plates were incubated for 24 hours at 37°C.  
Planktonic bacteria were removed from the wells through aspiration of the liquid without 
disturbing the biofilm followed by gently washing with PBS three times. Heat fixation of the 
biofilm bacteria was achieved by heating the microtiter plate at 60°C for one hour. Once the 
biofilm was fixed, it was stained using 100 µL of crystal violet solution. Crystal violet not 
absorbed by the biofilm was removed by gently rinsing with water. At that time, a de-staining 
solution composed of 7.5% acetic acid, 10% methanol, and water was used to dissolve the 
absorbed crystal violet. Absorbance measurements were obtained at λ=540 nm using a plate 
reader spectrophotometer (Biotek ELx800, Winooski VT, USA). The minimum biofilm 
inhibitory concentration (MBIC) is the concentration of antibiotic required to inhibit the 
formation of biofilm.  
Relationships between antibiotics was quantified using the fractional inhibitory 
concentration index (FICI).210, 211 FICI was determined for each antibiotic as follows, the MBIC 
for the antibiotic in combination was divided by the MBIC of each antibiotic alone. The FICI for 
each antibiotic was summed to acquire a final FICI value. FICI values < 1 were considered 
synergistic, ≥	1 and < 2 were additive, = 2 were indifferent, and > 2 were antagonistic. 
In Vivo Implant-Associated Biofilm Model 
All methods were approved and monitored for compliance by the animal use committee 
at UAMS and by the Animal Care Use and Review Office (ACURO) at the USAMRMC. A pilot 
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murine model with orthopaedic implant-associated infection212 was adapted to use a 
polymicrobial mixture of S. aureus (UAMS-1)213 and E. coli (ATCC 25922).214  
In the infected mouse pin model (UAMS – IACUC 3579), sterilized chitosan sponges 
were hydrated with antibiotic solutions. The sponges were hydrated with 5 mL of an antibiotic 
solution combination of ciprofloxacin and rifampin (10 mg mL-1 each).  NIH-Swiss mice 
C57BL/6, 8 - 12 weeks old, 16 – 18 grams in weight were anesthetized with Isoflurane and 
Avertin (400 - 600 µg g-1) and the adequacy of the anesthesia was confirmed by the toe pinch 
reflex and the reaction to light shined into the mice eyes. The left leg was cleaned with povidine 
iodine and rinsed with 70% ethanol.  An incision was made at the knee; a hole was drilled into 
the left distal femur with a 26-gauge syringe needle followed by a 23-gauge syringe needle. A 
sterile 1 cm x 600 µm diameter stainless steel Kirschner wire was inoculated with approximately 
104 colony forming units (CFUs) of UAMS-1 and 102 CFUs of ATCC 25922 and inserted into 
the femur. Placement of the pin within the femur can be seen in Fig. 4. 
 
FIGURE 4. Pictured is an x-ray that shows the 
placement of the pin within the left femur. The 




Chitosan sponges loaded with saline (negative control) or the combination of 
ciprofloxacin and rifampin at 10 µg mL-1 each were implanted adjacent to the contaminated 
implant (n = 12 per group). After surgical site closure, the mice were returned to their cages, 
monitored daily, and any that appeared moribund would be euthanized using CO2.  None of the 
study participants displayed any moribund attributes during the duration of the study. Animals 
were euthanized 7 days after the treatment, the wire implant and any associated femur tissue 
were removed for determination of viable bacterial CFUs remaining on/in each. The soft tissue 
was dissected from the bone and the femur was cut into small pieces, homogenized, and placed 
in a sterile saline. Wire implants were sonicated and vortexed in sterile PBS. After overnight 
incubation at 37° C, the homogenates were diluted, plated on agar plates, and the viable 
microbial colonies were counted along with the colonies remaining on the pin and bone. 
Bacterial clearance was defined as an apparent bacterial CFU count of zero. 
Statistical Analysis 
Statistical analysis of results was performed using Sigma Plot (Systat Software, Inc., San 
Jose, CA, USA). One way Kruskal Wallis Analysis of Variance (ANOVA) was used to 
determine differences between CFUs retrieved from implants, with p values of < 0.05 being 
considered statistically significant. Dunn’s post hoc analysis was used to compare groups 
pairwise and determine p values. Fisher exact tests of contingency tables was used to compare 
the rate of clearance for implants in antibiotic-loaded groups to controls, with Bonferroni post 
hoc correction in cases of multiple comparisons. No other statistical analysis was performed as 




In Vitro Elution 
Results from the elution study showed that rifampin elutes, virtually 100%, from its 
delivery device within three days (Fig. 5). Ciprofloxacin’s elution profile while still displaying a 
burst effect was sustained throughout the duration of the study (Fig. 6).  
 
 
FIGURE 5. Bar graph of the mean ± standard deviation of rifampin concentration in 





FIGURE 6. Bar graph of the mean ± standard deviation of ciprofloxacin concentration in 
sponge eluates (n = 5) over 7 days. 
 
In vitro antibiotic activity 
Eluates from chitosan-based local delivery devices could inhibit P. aeruginosa (ATCC 
27317) (Fig. 7) and S. aureus (Cowan I ATCC 12598) (Fig. 8) through the duration of the seven-
day study when solubility was addressed. Chitosan sponge eluates from proof-of-concept (POC) 
elution could inhibit, on average four days, P. aeruginosa (ATCC 27317) (Fig. 7) and S. aureus 




FIGURE 7. Zone of inhibition (ZOI) results of sponge eluates tested against P. aeruginosa (ATCC 
27317). On the left of each sponge group were the results before the solubility issue was addressed. 





FIGURE 8. Zone of inhibition (ZOI) results of sponge eluates tested against S. aureus (Cowan I 
ATCC 12598). On the left of each sponge group were the results before the solubility issue was 
addressed. The plates on the right were achieved as the solubility of rifampin was actively addressed. 
 
In Vitro Synergy Assay 
Results from the synergy assay showed an additive effect between ciprofloxacin and 
rifampin against P. aeruginosa (ATCC 27317) with a FICI value of 1 (Table 1) and no 
discernible effect against S. aureus (UAMS-1) (Table 1). 
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In Vivo Implant-Associated Biofilm Model 
The combination of ciprofloxacin and rifampin could completely clear both the pin (Fig. 
9) and the bone (Fig. 10) of S. aureus CFUs at seven days. S. aureus clearance can be seen with 
SEM images (Fig. 11). While some E. coli colonies were retrieved from the bone tissue in 
negative saline controls without loaded antibiotics (Fig. 12), there were no viable colonies after 
seven days on the implant (Fig. 13). 
 
FIGURE 9. Dot plot of each animal’s remaining CFUs after implant retrieval. Black 





FIGURE 10. Dot plot of each animal’s remaining CFUs after implant retrieval. 





FIGURE 11. SEM image taken of the pin for a PBS pin with no antibiotic loading (top) with a 





FIGURE 12. Dot plot of each animal’s remaining CFUs after implant retrieval. Black 






FIGURE 13. Dot plot of each animal’s remaining CFUs after implant retrieval. Black 
dot represents mean for the group. 
 
DISCUSSION 
The primary purpose of this study was to ascertain if dual antibiotic local drug delivery 
from chitosan sponges could assist with inhibiting biofilm formation. During the study 
antibiotics were actively released from chitosan sponges at levels that were shown to be 
inhibitory. This study exhibits that this antibiotic combination may be introduced into a local 
delivery system to release active concentrations for infection inhibition. The study results also 
suggest a potential additive relationship against Gram-negative P. aeruginosa for ciprofloxacin 
and rifampin. Gram-negative bacteria, specifically P. aeruginosa, has a history of being 
persistent,188, 190 treatment options consisting of antibiotics with different mechanisms of action 
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that are additive may eliminate the persister bacterial cells in potential clinical applications. No 
discernible effects, synergistic, additive, antagonistic, or indifferent, were obtained against the 
Gram-positive S. aureus due to the combination completely inhibiting the growth. While the 
ability to inhibit biofilm was not determined by the in vitro synergy assay it was shown that this 
combination can inhibit S. aureus growth. The efficacy of this treatment method was further 
investigated using a known model of implant infection. Results revealed complete clearance of 
Gram-positive S. aureus when dual-loaded chitosan sponges were introduced. The combination 
of ciprofloxacin and rifampin performance under physiological conditions, which are difficult to 
simulate in vitro, offers more validation that the combination may be a potential treatment option 
for practicing physicians. 
The combination of ciprofloxacin and rifampin may provide improved treatment for 
infection prevention in musculoskeletal wounds and/or injuries. Ciprofloxacin is a 2nd 
generation fluoroquinolone that has been clinically effective at inhibiting some bacteria.67-76 
Quinolones/fluoroquinolones have proven to be effective against bacteria due to their ability to 
prevent the DNA from unwinding and duplicating.60 Ciprofloxacin is one of the numerous 
fluoroquinolones that have extensive clinical usage for the treatment of Gram-negative and some 
Gram-positive bacterial pathogens.63, 65, 66, 78-83 Rifampin has emerged as a major player in 
antibiotic combination therapy to combat biofilm among other infections. Rifamycins, 
represented by rifampin, specifically inhibits bacterial DNA-dependent RNA polymerase by 
blocking the RNA chain initiation step of bacterial DNA transcription to messenger RNA that is 
needed to synthesize bacterial proteins.97,62 Rifampin is bactericidal against Gram-positive 
bacteria and diffuses well into biofilm where it perpetuates it bactericidal ability.62 Disruption of 
biofilm is within the scope of rifampin, however rifampin-resistant mutants may be selected.62 
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Rifampin requires to be used in conjunction with other antibiotics as a result.62 Rifampin has 
been tested with a number of other antibiotics for potential synergistic effects against 
Acinetobacter baumannii,3 Klebsiella pneumoniae,215 and S. aureus216 among others. 
Ciprofloxacin has been investigated in conjunction with several antibiotics against P. 
aeruginosa3, Enterbacteriaceae and D. streptococcal8 to name a few. Very few studies have 
reported the effects of the combination of ciprofloxacin and rifampin against the strains of 
bacteria tested here. In a study by Zimmerli et al., a cure rate of 100% was achieved for those in 
the ciprofloxacin-rifampin group in patients with culture-proven Staphylococcal infection 
associated with stable orthopedic implants.164 Ciprofloxacin and rifampin was the most effective 
treatment regimen in reduction of MRSA in bone in rats with experimental osteomyelitis.217 The 
groups tested were vancomycin, vancomycin-rifampin, ciprofloxacin, ciprofloxacin-rifampin, 
rifampin, and a control group.217 Widmer et al. concluded that combination therapy with 
rifampin and a quinolone should be considered for patients with orthopedic implant-related 
infections if the implant cannot be removed.218 The Widmer study centered around patients with 
infections resulting from staphylococci or streptococci.218  
 The additive effect against P. aeruginosa shows promise for this combination. Complete 
inhibition of S. aureus was validated with results from most phases of the study with culmination 
coming from the implant-associated biofilm model. Biofilm synergy assay results for S. aureus 
were not able to be determined as the concentrations of the antibiotics completely inhibited 
growth. Future investigations are planned with lower concentrations of both antibiotics. There 
have been recent studies that were shown to completely clear P. aeruginosa and S. aureus on 
implants through systems consisting of phospholipid coatings impregnated with amikacin and 
vancomycin219 or injectable hydrogels containing high doses of gentamicin220, respectively. One 
41 
 
of the main disadvantages of chitosan sponge based local delivery systems is their dependence 
upon diffusion, which may result in not all aspects of an implant receiving antibiotics above the 
MBIC.23, 27 Sponges have an advantage of being loaded with a customizable treatment solution 
immediately prior to application. Sponges do not require prefabrication in comparison with 
coatings or hydrogels, giving them practibility for quick interventions as needed, whether in the 
field or on the surgical table.220, 221 These results extended those previously obtained that 
demonstrate biofilm inhibition in soft tissue implant-associated models170 providing credence to 
activity in prevention of bone infection.   
One major limitation for this study revolved around the in vivo model. This resulted from 
the strain of E. coli (ATCC 25922) used, which was not robust nor readily form biofilms. The 
method was adapted from an osteomyelitis model of which the investigators reported issues with 
the use of this specific strain.214 In efforts to reduce or prevent severe morbidity and mortality 
that have previously occurred in polymicrobial models containing S. aureus and P. 
aeruginosa,170 E. coli was selected. Lack of the robust biofilm formation greatly limits our 
ability to generalize conclusions to polymicrobial infections. Future in vivo investigations of 
polymicrobial biofilm will be modeled to include a more pathogenic, biofilm-forming Gram-
negative bacteria, such as P. aeruginosa with an appropriate inoculum adaptation,174, 222, 223 with 
groups receiving no local delivery of antibiotics receiving systemic delivery. 
CONCLUSIONS  
The ability of ciprofloxacin and rifampin, in combination, to inhibit S. aureus and P. 
aeruginosa growth in an in vitro environment and S. aureus and E. coli when released from 
chitosan sponges in vivo illustrates the clinical potential of this local delivery approach for 
infection prevention in extremity trauma. Complete clearance or inhibition of contaminating 
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biofilm pathogens may be achieved with the implementation of these antibiotics loaded within 
chitosan sponges. 
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Biofilm can further complicate musculoskeletal wounds normally increasing treatment time, 
costs, patient morbidity, and required surgeries.1, 2, 215, 216 Antibiotic dosages that may be adverse to 
the patient are required to clear localized bacteria when administered systemically due to common 
vascular compromise in musculoskeletal wounds.3, 8 Chitosan local delivery devices and their 
development were in response to a clinical need for local delivery devices there are efficacious in 
clearance of bacteria, biocompatible, completely biodegradable, and allow tailored point-of-care 
loading.171, 188, 191, 224 Throughout the overall study these aspects were investigated to ensure that the 
chitosan-based local delivery systems tested actually fulfilled these requirements. Whereas, these 
secondary investigations were not directly related to the hypothesis however, they support a primary 
aspect of this research.    
Multiple variations of chitosan sponges in parallel with a commercially available chitosan 
sponge were tested during the proof of principle phase. This was done to determine which variation 
would be most functional throughout the duration of the overall study. Table 1 in Appendix A 
displays all variations and their composition. Zone of inhibition (ZOI) sponge eluate activity results 
are displayed in Appendix B. Based on the results, it appears that the chitosan content affects the 
duration of the sponge eluate at bacterial inhibition. During this phase activity lasted on average 
through three days, which could be clinically relevant if all present bacteria was 100% eradicated. 
However, if some bacteria remain after the three days it could lead to the formation of persister cells 
and could result in antibiotic resistance. Parker et al. reported an initial burst release of loaded 
vancomycin from neutral chitosan/PEG and chitosan sponges after one hour, experiencing a 
significant decrease in eluted antibiotic thereafter.224 An investigation by Noel et al. of in vitro 
release properties of vancomycin from chitosan sponges fabricated with lactic and acetic acid showed 
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an initial burst release of loaded vancomycin after one hour, while also experiencing a significant 
decrease in eluted antibiotic thereafter.190 As demonstrated in Chapter III, sponge eluate activity 
could be extended throughout seven days adding credence to the use of rifampin and ciprofloxacin in 
a clinical application for bacterial inhibition, while Noel et al. found that virtually all of the loaded 
vancomycin was released after 72 hours.190 Vancomycin concentrations found by Parker et al. were 
above the MIC through 24 hours, eluates utilized for turbidity testing only remained active against S. 
aureus through six hours.224 Noel et al. found that the levels of 32 vancomycin eluates remained 
above the MIC active through 72 hours.190 Noel et al. also reported amikacin eluates from chitosan 
sponges remaining active through 48 hours.190 Turbidity testing performed on ciprofloxacin and 
rifampin loaded sponge eluates during the preliminary proof-of-principle study were active through 
three days. Additionally, the prior studies by Parker et al. and Noel et al. were single-loaded in 
comparison with the dual-loaded implemented for this study. An additional test for sponge eluate 
activity was conducted and its result can be seen in Appendix C. The turbidity test was conducted in 
parallel to the ZOI test to validate the procedure. Turbidity results confirmed what was seen with the 
ZOI results. Due to potential inaccurate readings, because of rifampin’s color turbidity testing may 
not be advantageous. Rifampin, when properly in solution, will have an orange color, which could 
affect the absorbance, which is what is measured in turbidity.  
Degradation of any local delivery device is advantageous over delivery systems that do 
not degrade. One of the more prevalent local delivery mechanisms practicing clinicians employ 
is PMMA beads, which maintain a steady stable elution profile. Some drawbacks of PMMA 
beads include, but are not limited to, lack of degradation and introduction of addition surface 
area into the surgical site or wound bed for bacterial attachment. Chitosan sponges possess the 
ability to biodegrade with no adverse byproducts. To confirm this two experimental degradation 
methods were used during the study on chitosan sponges, enzymatic and oxidative.171 As seen in 
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Appendix D (Figure 19), enzymatic degradation with lysozyme was minimal whereas oxidative 
degradation was more robust (Figure 18) and useful in ranking degradation rates/amounts of different 
local delivery constructs. Oxidative testing is gaining more uses and its physiological representation 
is still being determined for chitosan-based systems.171 Chitosan degradation by lysozyme has been 
established but to truly understand degradation of chitosan in vivo implantation is required and can be 
determined using histological methods.171   
Chitosan sponges should be able to accept the required amounts of any tailored antimicrobial 
point-of-care loading necessary for desired treatment. This functional need was investigated by 
subjecting the chitosan sponges to a swelling ratio test. All tested sponges returned the ability to be 
loaded at >1000% with an aqueous solution of their initial mass, Appendix D (Table 4). Chitosan 
sponges possessing the ability to absorb more than 10 times their mass makes them good candidates 
for short-term local delivery treatment options. 
Biocompatibility evaluation was conducted and reported in Chapter III but in vitro tests of 
cytocompatibility of the chitosan sponges were conducted prior and the results are seen in Appendix 
F. BioSponge had the highest cytocompatibility of the tested sponges at 24 and 72 hours (Figures 21 
& 22). This positive outcome was expected since this product has been tested extensively by Bionova 
Medical and approved to be marketed as a wound dressing by the Food and Drug Administration 
(FDA). Study results revealed that the least cytocompatible of the tested chitosan sponges was the 
2.0% chitosan sponge. There was more deviation seen in the 24-hour results compared with 72-
hour. BioSponge cell proliferation exceeded the control (TCP empty well), which had no contact 
with any sponge. This cell number increase from this evaluation introduces the possibility that 
BioSponge may promote cell growth. More precise evaluations on cell function are needed for a 
more complete determination because cell culture does not truly duplicate the conditions and the 
whole story of in vivo compatibility. Standard deviation in the 1.5% chitosan sponges could 
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negate that fact that it exceeded the control at both designated times. For the 72-hour study, 
every sponge exceeded the control. Viable cell numbers decreased at 72-hours for BioSponge 
and 1.5% chitosan/0.5% PEG but increased for the 2.0% chitosan sponge in comparison to 24-
hours results. This result could have come from improper loading/seeding techniques or the 
loading of the sponges into the wells during 24-hour study. Another possible factor could be that 
the cells needed time to adapt to the sponges. A longer study will be suggested for future 
experimentation. 
Study limitations include the murine size, which has a small defect size and may not be 
physiologically representative of infected, complex, and large wounds in a clinical setting. Sections 
of the sponges were tested due to limitations in the animal wound size and in available testing 
parameters. Results may or may not be indicative of testing the complete sponge structure in a large 
complex musculoskeletal wound. However, the practicing clinician has the ability and may choose to 
re-size the chitosan sponge for the desired treatment plan. All in vitro studies were performed under 
controlled conditions, which may not directly correlate to in vivo performance. Ciprofloxacin and 
rifampin were tested together and not separately. This dual antibiotic use was selected and completed 
due to the previously reported issue that rifampin must be used in combination with another 
antibiotic. Most in vitro studies were performed during a reduced time-frame and all tested sponges 
















This body of work and the studies performed within it support inclusion of ciprofloxacin and 
rifampin as a treatment option when loaded as a point-of-care solution. The chitosan sponge eluates 
showed activity through seven days which support our use as a short-term treatment option. Through 
local and short-term use the treatment cocktail avoids the recent released literature and FDA reports 
of adverse effects resulting from systemic use of ciprofloxacin. Ciprofloxacin based on results 
complements rifampin, which was released completely at three days in similar fashion to prior 
studies.   
In vitro biofilm assay study results were inconclusive against S. aureus due to the 
combination completely inhibiting growth at the concentrations tested. Biofilm disruption was seen 
against P. aeruginosa offering support of the reported claim and selection of rifampin for this 
research. Further testing is needed at reduced concentrations, at minimum 3-fold below reported MIC 
values, to obtain viable results against S. aureus. Solubility of rifampin appeared to be temperature 
dependent, however contingent on specific application and treatment plan solubility may not be an 
issue. Recent unpublished ongoing studies are introducing powder rifampin in vivo, like the common 
vancomycin “sprinkle” and allowing physiological processes to solubilize. This proposed local 
delivery system required all antibiotics solubilized to load a desired concentration in the chitosan 
sponge. This study determined a method that allowed this to be accomplished without affecting the 
structure of the chitosan sponge in a detrimental way.  
Rifampin and ciprofloxacin cleared all bacteria in the in vivo functional murine model with 
no adverse effects to the mice. Although the results were not without a caveat as the biofilm-forming 
E. coli strain cleared was not robust. Future testing with a more robust Gram-negative bacterium, like 
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biofilm-forming P. aeruginosa, would be required to confirm activity against polymicrobial 
infection.  
In conclusion, a system that affords drug loading and tailored release to individual patient 
need and surgeon preference is advantageous in infection inhibition. The results presented in this 
body of work provide validation of the stated hypothesis: that engineered porous chitosan sponges, 
after being hydrated with ciprofloxacin and rifampin for short-term treatment, less than 14 days, 
would be effective at biofilm-related infection prevention. More in vivo testing is needed, as with 
most proposed treatment solutions, to confirm many of the reported conclusions, i.e. degradation, 
biofilm effects. With additional research the ciprofloxacin/rifampin combination may prove to be 
a viable option for local treatment amalgamation with standard surgical treatment of complex 
musculoskeletal injuries in infection prevention and biofilm-related infection prevention of 




























 To validate the efficacy of ciprofloxacin and rifampin when released from chitosan-based and 
other proven local delivery devices further in vitro and in vivo research must be conducted. 
Ciprofloxacin and rifampin should be investigated monogamously for elution and activity to 
determine if one effects the other. Solubility of rifampin with simply temperature (37° C) as a 
catalyst should be investigated, which may provide an easier method for complete dissolution. 
Investigation of pore size and structure when the chitosan sponge is singularly loaded is worth 
pursuing for many of the same reasons previously stated. While bacterial inhibition was the primary 
endpoint of the functional murine infected pin model, investigation of an established bacterial 
infection should be assessed during future studies. The functional infected pin model simulated metal 
hardware, a complement would be a functional model that simulates infected polymer implants. 
Although no adverse effects were seen at the antibiotic concentration used during the functional 
murine model future studies should address what concentrations are required for inhibition of each 
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APPENDIX A: DETAILED MATERIALS AND METHODS FOR CHAPTER III 
Chitosan Sponge Fabrication 
 Fisher Scientific (Pittsburg, PA, USA) supplied all materials unless noted. The 1.5% 
chitosan/0.5% PEG sponge fabrication consisted of Chitopharm S chitosan powder (Chitnor AS, 
Tromsø, Norway) with an 82 ± 2 DDA, 251 ± 17 kDa weight-average molecular weight (MW) 
and 2.013 ± 0.145 polydispersity index and polyethylene glycol (PEG) with a molecular weight 
of 6000 g mol-1 (Sigma Aldrich, St. Louis, MO, USA). The 2.0% chitosan sponge consisted of 
only Chitopharm S chitosan powder. Bionova Medical (Germantown, TN, USA) provided 
commercially available sterile BioSponge with proprietary composition. For the chitosan/PEG 
sponge 1% acidic acid v/v dissolved 0.5% PEG w/v in ultrapure water, additional chitosan/PEG 
sponges with varying chitosan content were fabricated in same manner (Table 1). The solution 
then dissolved 1.5% chitosan after complete dissolution of the PEG. An acid mixture of 0.75% 
lactic acid v/v and 0.25% acidic acid v/v dissolved 2.0% w/v chitosan in ultrapure water to make 
the 2.0% chitosan sponge, additional chitosan sponges with varying chitosan content were 
fabricated with same procedure (Table 1). Once complete dissolution was achieved 250 mL 
aliquots of the solutions were cast in 4 x 8 cm containers and frozen overnight at -20° C. 
Benchtop freeze dryers (LabConco, Kansas City, MO, USA) lyophilized the frozen solutions 
after they were removed from the freezer creating acidic dehydrated sponges.  Sodium hydroxide 
(NaOH) solutions of 600 mM and 250 mM assisted in the neutralization of the acidic chitosan 
and chitosan/PEG sponges, respectively. Sponges were covered in the appropriate NaOH 
solution for approximately seven minutes. At the expiration of the seven minutes the NaOH 
solution was removed and the sponges were washed with ultrapure water until their eluate tested 
for a neutral pH. Neutral sponges were then frozen again at -20° C for one hour and lyophilized 
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to create the neutral unsterilized sponges. Sterigenics (West Memphis, AR, USA) sterilized all 
fabricated twice lyophilized neutral using low dose gamma radiation (25 – 40 kGy).  
 Table 1. Composition of various chitosan sponges used during proof of principle phase of study. 
Chitosan Content Peg Content Acid Content Document Reference 
1% N/A 1% (0.75% LA, 0.25% AA) 1C 
1.5% N/A 1% (0.75% LA, 0.25% AA) 1.5C 
2% N/A 1% (0.75% LA, 0.25% AA) 2C 
0.5% 0.5% 1% AA PC 
1.0% 0.5% 1% AA 1PC 
1.5% 0.5% 1% AA 1.5PC 
BioSponge (proprietary content) B 
*Poly(ethylene glycol) (PEG), Acetic Acid (AA), Lactic Acid (LA) 
Antibiotic Dissolution 
 Rifampin (Fisher Scientific, Fair Lawn, New Jersey, USA) and ciprofloxacin·HCl (Acros 
Organics, Geel, Belgium) were weighed out, independently, to make 5 mg mL-1 solutions in 
ultrapure water. A 0.1 N HCl solution (25° C) was prepared in ultrapure water and 100 mL was 
added to a beaker. The temperature was raised to 37° C, rifampin, and 100 mL of ultrapure was 
added, temperature was brought to 37° C. If any rifampin was not completely in solution drops 
of 0.1 N HCl was added at 37° C until complete dissolution was achieved. Once complete 
dissolution of rifampin occurred, the measured amount of ciprofloxacin was added to the 
solution and the pH was recorded. A solution of 500 mM NaOH (25° C) in ultrapure water was 
prepared. Drops of the NaOH were added to the solution to increase the pH to an acceptable 
range that would not affect the chitosan sponge structure. The final pH of the antibiotic solution 
at 37° C was 5.86. Attempts to increase the pH above 5.86 resulted in antibiotics falling out of 
solution. The solution was transferred to an appropriate volumetric flask and ultrapure water was 
added to complete the solution.     
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In vitro elution 
 All procedures contained within this section were conducted within an aseptic 
environment. All sterilized sponges were sectioned to and weighed to nominal masses of 25 mg. 
Dehydrated sectioned sponges (n = 5) were separately placed in containers with ~10 mL of the 5 
mg mL-1 ciprofloxacin/rifampin antibiotic solution for 10 minutes. Sponges were carefully 
removed from the container and gently placed in 125 mL NALGENE containers, which had 
adequate space for the sponges to keep their natural structure. The mass of the newly antibiotic 
hydrated sponges was recorded.  
 Sterile 1X phosphate buffered saline (PBS) was made from 10X PBS, with ultrapure 
water and a Sterilmatic autoclave (Market Forge, Boston, MA, USA). Sterile 1X PBS (30 mL) 
was placed in each container, which fully submerged the sponge. Containers were then placed in 
an incubator (LabDoctor Mini Incubated Shaker, MidSci, St. Louis, MO, USA) at 37° C under 
constant motion of 30 rpm. At predetermined time intervals of 1 – 7 days, systems were removed 
daily from the incubator and samples of 10 mL, in 2 mL aliquots, were taken. Systems that were 
slated for the day of sample were discarded. Systems that were not slated for the day of sample, 
had an aspirator remove the excess fluid, PBS was restored, and the systems were placed back 
into the incubator at the same conditions as previously stated. This process continued until day 
seven at which point all systems had been properly sampled and discarded. Eluates were stored 
immediately after collection in a freezer at -20° C until further analysis.  
Eluate Concentration Analysis 
High-performance liquid chromatography (UltiMate 3000, Thermo Scientific, West Palm 
Beach, FL, USA), formerly known as high-pressure liquid chromatography, determined the 
concentration of ciprofloxacin and rifampin in the sponge eluates. Stock concentrations of 1 mg 
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mL-1 were made for ciprofloxacin and rifampin for the standard curve and to randomly verify 
detection method throughout the sequence. HPLC grade methanol (30%), HPLC grade 
acetonitrile (28%), 55 mM dipotassium phosphate (38%), and 1.0 M phosphoric acid were 
combined to create the primary mobile phase (MP1). The primary mobile phase implemented to 
detect both ciprofloxacin and rifampin was modeled after Liu et al.194 Detection of both 
antibiotics with one primary mobile phase required an additional buffer solution (MP2) which 
consisted of 1.0 M phosphoric acid and 55 mM dipotassium phosphate. The UltiMate 3000 has 
four pumps which made this adaptation possible. MP1 was placed on one pump and MP2 was 
fed through another pump.  
To ensure MP1 accurately detected targeted antibiotics 1.5 mL of stock concentrations 
were placed in 2 mL HPLC vials and analyzed. Now only MP1 was used to detect the targeted 
antibiotic ciprofloxacin or rifampin. Once UV-Vis detection, using 2 µL injections, of each (n = 
10) was validated by same retention time, height, and sharpness of peak, a gradient method 
needed to be optimized to detect both analytes in each sample with one pass. This is necessary if 
the retention time of the antibiotics are close enough to introduce potential interference, possibly 
skewing results. The adapted MP1’s primary use was detection of rifampin therefore the focus 
was on ciprofloxacin. Optimization required adjusting the amount of MP1 and MP2 to 
percentages that efficaciously detected ciprofloxacin. After numerous iterations, the final 
percentage that detected ciprofloxacin was 60% MP2 and 40% MP1. The new detection 
parameter required validation for detection of both ciprofloxacin and rifampin. A new stock 
concentration (1.5 mL) that consisted of 1 mg mL-1 ciprofloxacin and 1 mg mL-1 rifampin was 
placed into 2 mL HPLC vial for analysis. For efficacious analysis of sponge eluates, a gradient 
method needed optimization. To accomplish this all the previously mentioned stock 
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concentrations were implemented. The chromatographic separation detection gradient method 
required numerous iterations before determining one that returned the desired detection 
parameters. The gradient method determined for this analysis consisted of a four-minute 
equilibration to ensure 40% PM1 and 60% PM2 at which point the injection was initiated. This 
was held steady through three minutes at which point the gradient was ramped up to 100% PM1 
and held there for the duration (12 minutes) of the method. Validation of said gradient method 
required detection of ciprofloxacin and rifampin from either of the vials in a succession of 25. 
The flow rate was 1.5 mL min-1 with a BDS HYPERSIL C18 reverse phase column (Thermo 
Scientific, West Palm Beach, FL, USA), held at 30° C set by the method and possible due to the 
UltiMate 3000.  Ciprofloxacin was read at λ = 280 with a bandwidth of 4 and a retention time of 
2.38 minutes.  Rifampin was read at λ = 333 with a bandwidth of 4 and a retention time of 11.21 
minutes. Sponge eluate samples were thawed and were plated in a 96-well plate (250 µL). Each 
96-well plate contained two columns of known concentrations for continued method validation 






FIGURE 14. Bar graph of mean ± standard deviation of ciprofloxacin concentration 





FIGURE 15. Bar graph of mean ± standard deviation of rifampin concentration in 
sponge eluates (n = 4) during preliminary testing. 
 
Scanning Electron Microscope Image Acquisition (Sponge Pore Structure)  
The dehydrated sponges (n = 4) were sectioned to 6.25 cm2 with half remaining 
dehydrated and others loaded with the ciprofloxacin/rifampin antibiotic cocktail (pH 5.86). 
Samples were loaded independently for 10 minutes with excess solution removed by aspiration. 
Sponge samples needed to be further reduced in size for imaging purposes using a Nova Nano 
scanning electron microscope (SEM) 650 Field Emission System. Liquid nitrogen was 
implemented to flash freeze the samples allowing for smaller pieces to be cracked from them 
with tweezers. The samples were placed in a dewar and placed in liquid nitrogen until frozen. 
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Pore structure inside the sponge, which would have been harmed by cutting, was preserved using 
this method. Once the samples were of appropriate size, they were attached to SEM sample 
holders using double-sided carbon tape and dried in a vacuum oven (21 inHg) for 72 hours at 40° 
C. Immediately prior to imaging, samples were coated with a 10 nm layer thick of gold-
palladium. Surface area and cross sectional images were taken with an excitation voltage of 








































APPENDIX C: CHITOSAN SPONGE ELUATE TURBIDITY 
Rationale 
Bacteria reside in vivo within an aqueous environment. Blood and other aqueous 
solutions provide transport possibilities of bacteria from one location to another.170, 188, 193 
Turbidity testing is a pseudo model of this clinical scenario. Eluate samples are tested against 
bacteria floating in an aqueous environment to determine whether the treatment can inhibit 
growth within solution.  
Pseudomonas aeruginosa Turbidity 
P. aeruginosa (Schroeter) Migula ATCC 47085, commonly referred to as PAO-1, was 
the bacterial strain used during this testing process. The bacterium was diluted 1:50 in TSB and 
grown overnight in an incubator at 37 °C. The eluate sample (200 µL) was placed into a 5 mL 
polystyrene round-bottom tube (Falcon) with 1.75 mL TSB, and 50 µL PAO-1. Positive controls 
consisted of 1.95 mL TSB and 50 µL PAO-1, while negative controls contained 1.8 mL TSB and 
200 µL eluate sample. The tubes containing the mixtures was placed in an incubator at 37 °C for 
24 h. Once the 24 h were passed the tubes were removed from the incubator and absorbance was 
read at λ = 540 on a Spectronic 200 (Thermo Scientific, Waltham, MA, USA). The results can be 
seen in Table 2.    
Staphylococcus aureus Turbidity 
S. aureus ATCC 49230 (osteomyelitis clinical isolate), often referred to as UAMS-1, was 
the bacterial strain used during this testing procedure due to its confirmed contribution to bone 
infections, being cultured from osteomyelitis. The bacterium was diluted 1:5 in TSB and grown 
overnight in an incubator at 37 °C. The eluate sample (200 µL) was placed into a 5 mL 
polystyrene round-bottom tube (Falcon) with 1.75 mL TSB, and 50 µL UAMS-1. Positive 
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control consisted of 1.95 mL TSB and 50 µL UAMS-1, while negative controls contained 1.8 
mL TSB and 200 µL eluate sample. The tubes containing the mixtures were placed in an 
incubator at 37 °C for 24 h. After the 24 h had passed the tubes were removed from the incubator 
and absorbance was read at λ = 540 nm on a Spectronic 200. The results can be viewed in Table 
3. 
Results 
The results were in agreeance with the ZOI results seen in Appendix B. During this phase 
of the investigation no efforts were made to address the solubility of either antibiotic. The results 
were still comparable to other previous tested antibiotic combinations and their eluates from 
chitosan sponges.  
Table 2. Results of turbidity testing for Pseudomonas aeruginosa, (-) indicates inhibition and (+) 
indicates growth. 
Day 0.5% Peg 1.5% Chitosan 2.0% Chitosan BioSponge 
1 - - - 
2 - - - 
3 - - - 
4 + + - 
5 + + - 
6 + + + 
7 + + + 
 
Table 3. Results of turbidity testing for Staphylococcus aureus, (-) indicates inhibition and (+) indicates 
growth. 
Day 0.5% Peg 1.5% Chitosan 2.0% Chitosan BioSponge 
1 - - - 
2 - - - 
3 - - - 
4 + - - 
5 + + + 
6 + + + 
7 + + + 
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APPENDIX D: CHITOSAN SPONGE DEGRADATION 
Rationale 
Degradability of chitosan sponges is an proposed advantage in clinical applications.171, 
172, 225-227 For the purpose of this study, degradation timing shortly after functional elution 
completion would be optimal. Degradability was ascertained using two methods, enzymatic and 
oxidative.135, 172, 188, 226, 228-234 For both degradation studies sponges were be fabricated and 
sectioned as they were for the elution study and SEM imaging (APPENDIX A). Oxidative 
accelerated in vitro degradation aids in the determination of overall degradation of the sponge 
types for further characterization of longer term in vivo degradation in reduced time frames and 
was investigated as a result.235-238 In vitro enzymatic degradation testing with lysozyme has been 
established as a physiological representation of in vivo degradation.135, 239-242  
Oxidative Degradation 
Sponges used for this phase of testing were fabricated or obtained as detailed in 
Appendix A. Sectioned sponge masses were recorded. Sponges were hydrated and had in vitro 
oxidative degradation evaluated in bacteriological petri dishes 100 x 15 mm (Falcon, Corning, 
NY, USA). The samples were hydrated for 10 minutes in 20 mL sterile 1X PBS; excess solution 
was removed by aspiration. Once the sponges were hydrated they were submerged in 30 mL of 
solution consisting of 1x sterile PBS, 3% H2O2, and 0.1 M CoCl2. Upon submersion, samples 
were placed at 37 °C in the LabDoctor Mini. Samples were collected at 3.6, 7.2, 10.8, 14.4 and 
18 hours from the beginning of the study. Since this degradation method is accelerated the time 
points (18 hours ÷ 5) were adjusted to mimic (ten days sampled every two days) those needed for 
enzymatic degradation with lysozyme. Solution was refreshed at all collection intervals. 
Collected samples were placed in an oven at 80 °C and allowed to thoroughly dry. When dried, 
78 
 
the mass of the sponges was measured and recorded. Oxidative sponge mass percent remaining 
can be viewed in Figure 18. 
Enzymatic Degradation 
 Sponges used for this phase of testing were fabricated or obtained as detailed in 
Appendix A. Sample sponges (n = 4) were sectioned to 9 cm2. Sectioned sponge masses were 
recorded. Sponges were hydrated and had in vitro enzymatic degradation evaluated in Falcon 
bacteriological petri dishes 100 x 15 mm. The samples were hydrated for 10 minutes in 20 mL 
sterile 1x PBS; excess solution was removed by aspiration. Once the sponges were hydrated they 
were submerged in a 30 mL of solution consisting of 1x sterile PBS, 1 mg mL-1 lysozyme, and 
1% antibiotic/antimycotic (AB/AM), containing penicillin, streptomycin, and amphotericin B. 
After submersion, the sponges were placed in the LabDoctor Mini at 37° C. The samples were 
collected every two days for duration of study (10 days). When samples were collected all 
PBS/lysozyme solution was refreshed in uncollected samples. Uncollected samples were 
returned to incubator until the next sample collection time was attained, at which time the 
process repeated until all predetermined time points were achieved. Collected samples were 
placed in an oven at 80° C and allowed to completely dry. Once dried, the mass of the sponges 
was measured and recorded. Enzymatic sponge mass percent remaining can be viewed in Figure 
19. 
Results 
 The degradation was linear for the oxidative through four time points. Clear degradation 
advantages were seen for the chitosan sponge that contained PEG, however the purpose was not 




FIGURE 18. Bar graph of mean ± standard deviation of sponge remaining mass as a 
percentage when subjected to oxidative mediated testing. Five samples were taken over 






FIGURE 19. Bar graph of mean ± standard deviation of sponge remaining mass as a 
percentage when subjected to lysozyme mediated testing. Five samples were taken every 















APPENDIX E: SWELLING RATIO OF CHITOSAN SPONGES 
Rationale 
 Local delivery systems should be able to be loaded with clinician’s choice of antibiotics, 
and accept the necessary volume to properly deliver concentrations of antibiotics above the MIC. 
Chitosan sponges’ ability to be loaded was determined through implementation of a swelling 
ratio study.  
Materials and Methods 
Sponges were fabricated or obtained as detailed in Appendix A. Sponges (n = 4) were 
sectioned (6.25 cm2) and independently weighed. Sectioned sponges were placed in 250 mL 
containers large enough for the section to lie flat. Sponges were hydrated with 30 mL of 1X PBS 
for 10 minutes. At expiration of the 10 minutes, sponges were removed with efforts taken for 
excess fluid to drip before loaded weight was measured. Pre- and post-hydration weights were 
used to determine the swelling ratio for each sponge investigated. Results can be seen in Figure 
20.  
Results 
 All sponges possess an ability to absorb at least 10 times their initial mass. The amount of 




FIGURE 20. Scatter plot showing mean ± standard deviation of tested sponges (n = 5) 
















APPENDIX F: CHITOSAN SPONGE CYTOCOMPATIBILTY 
Rationale 
Any successful local delivery based treatment method must be able to inhibit bacteria 
with minimal adverse effects. Sterile sponges were used in the cytocompatibility study phase. 
Once the study proved that the proposed combination therapy had good elution profiles and 
sponge eluates were active against bacteria cytocompatibility was investigated. 
Materials and Methods  
The sponges used for this phase were fabricated or obtained as detailed in Appendix A. 
The materials used for this experiment are: NIH3T3 cancerous fibroblasts cells, 0.75 cm2 48-well 
plates, High Glucose Dulbecco’s Modified Eagle Medium (DMEM) cell media, 96-well plates 
(Costar), Promega Cell Titer-Glo Luminescent Cell Viability assay, 70% ethanol, and chitosan 
sponges (n = 5). The cells were in media, which consisted of 2 mL DMEM, 10% fetal bovine 
serum (FBS), and 1% AB/AM. The 1% AB/AM contained penicillin, streptomycin, and 
amphotericin B. Cells were suspended in 6 mL of DMEM cell media and vortexed in preparation 
for the cytocompatibility study. NIH3T3 cells were seeded/pipetted into 48-well plates at 150µL 
per well and incubated overnight promoting cell attachment to the wells. Controls were tested 
therefore 20 wells were seeded with 150µL of cells. After 24 hours, three types of chitosan 
sponges (2.0% chitosan, 1.5% chitosan/0.5% PEG, and BioSponge) were added to the wells 
containing the cells. Each sponge was sectioned to fit inside the well plates (< 0.75 cm2). After 
placing sponges in the wells, an additional 150 µL of DMEM cell media was added to each well 
including controls. The plates were then placed in the incubator at 37° C with 5.0% CO2 
atmosphere overnight promoting proliferation. Two plates were required due to the time points 
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being 24 and 72 hours. Plates were removed at their time point and sponge samples were 
removed, media was refreshed every 24 hours.  
 To perform the Cell Titer Glo luminescence assay, 50 µL of cell-titer was pipetted into 
each well and the plate is shaken lightly. Light shaking of the plate mixes the Cell Titer Glo with 
the cell media producing a bright yellow color. After the prior step, 50 µL samples were 
removed from each well and transferred into a white polystyrene 96-well plate, taking care to 
interchange the pipette tip after each well. The 96-well plate was placed in a Gen5 microplate 
reader and luminescence at λ = 540 nm was read with its imaging software. This is correlated 
with the number of cells remaining because the Cell Titer Glo mixture results in cell lysis thus 
generating a luminescent signal proportional to the amount of ATP (adenosine-5-triphosphate) 
present. The amount of ATP is directly proportional to the number of cells. In addition, imaging 
techniques were used to visually detect cell behavior.  Healthy growing cells are viewed as 
spindle shaped, branching out and connected. A representative micrograph can be seen in Figure 
7, which was similar for both time points and all tested sponges.  
Results 
Results from luminescence (Figures 21 & 22) and micrographs agree, only one 
micrograph displayed due to extreme similarities (Figure 20). This supports the idea that chitosan 




FIGURE 21. Appearance of NIH3T3 cells at 24-hours after 
contact with BioSponge. 
 
 
FIGURE 22. Bar graph displaying mean ± standard deviation of cell viability after 
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